Abstract: A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor, and/or PKM2 inhibitor.

Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

Abstract: Devices for delivering a controlled concentration of an agent are provided. The device includes a reservoir for the agent and a flow control portion operably connected to the reservoir. The device also includes a valve for releasing the agent from the flow control portion and a pump for flowing air to mix with the agent released by the valve and for flowing the agent and air mixture out of the device. Methods of delivering a vaporized agent to a subject are also provided. The methods include storing a liquid agent in a reservoir of a device and flowing the agent into a flow control chamber to change the agent to a gas. The methods also include mixing the agent in gas form with air and flowing the agent and air mixture out of the device to be delivered to a subject.

Abstract: A method of lowering cholesterol and/or PCSK9 levels in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to reduce serum cholesterol and/or PCSK9 levels.

Abstract: A method of treating cardiovascular disorders and diseases in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.

Abstract: Systems and methods are provided for non-invasive measurement of endogenous S-nitrosothiols and related measurements thereof. One or more sensors non-invasively measures a set of one or more biometric parameters within a region of interest of a subject to provide a time series of measurements for each of the set of biometric parameters. A medium stores machine-readable instructions that are executable by an associated processor to perform processing comprising receiving the time series of measurements of the biometric parameter, generating, using a predictive model, a value representing an endogenous S-nitrosothiol content of tissue within the region of interest from the time series of measurements of the biometric parameter, and providing, by a user interface, the value representing the endogenous S-nitrosothiol content of tissue within the region of interest to a user.

Abstract: A method of lowering cholesterol and/or PCSK9 levels in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to reduce serum cholesterol and/or PCSK9 levels.

Abstract: Devices for delivering a controlled concentration of an agent are provided. The device includes a reservoir for the agent and a flow control portion operably connected to the reservoir. The device also includes a valve for releasing the agent from the flow control portion and a pump for flowing air to mix with the agent released by the valve and for flowing the agent and air mixture out of the device. Methods of delivering a vaporized agent to a subject are also provided. The methods include storing a liquid agent in a reservoir of a device and flowing the agent into a flow control chamber to change the agent to a gas. The methods also include mixing the agent in gas form with air and flowing the agent and air mixture out of the device to be delivered to a subject.

Abstract: A method of treating coronavirus infection, post-acute sequelae of coronavirus infection, and viral mediated respiratory distress in a subject in need thereof includes administering to the subject a therapeutically effective amount of agent that promotes, increases, and/or induces hemoglobin nitrosylation within red blood cells (RBCs) and GSNO levels in the lung or airways of the subject.

Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

Abstract: A method of treating cardiovascular disorders and diseases in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.

Abstract: An aldoketo reductase inhibitor includes a xanthene analogue.

Abstract: A method of treating a disorder associated gasotransmitter signaling in a subject in need thereof includes modulating the microbiota of the subject to modulate microbiota gasotransmitter production and modification of the subject's proteome to treat the disorder in the subject.

Abstract: A method of treating coronavirus infection, post-acute sequelae of coronavirus infection, and viral mediated respiratory distress in a subject in need thereof includes administering to the subject a therapeutically effective amount of agent that promotes, increases, and/or induces hemoglobin nitrosylation within red blood cells (RBCs) and GSNO levels in the lung or airways of the subject.

Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

Abstract: A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor, and/or PKM2 inhibitor.

Abstract: A method of lowering cholesterol and/or PCSK9 levels in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to reduce serum cholesterol and/or PCSK9 levels.

Abstract: Devices and methods are provided herein for exchange between a first agent and a second agent. The device includes a first chamber having a first inlet and a first outlet with a first flow passageway extending between the first inlet and the first outlet for flowing a first agent through the first chamber. The device also includes a second chamber having a second inlet and a second outlet with a second flow passageway extending between the second inlet and the second outlet for flowing a second agent through the second chamber and a membrane positioned between the first flow passageway and the second flow passageway to allow exchange through the membrane of the first agent with the second agent. Methods of nitrosylating blood and methods of manufacturing the device are also provided.

Abstract: Devices for delivering a controlled concentration of an agent are provided. The device includes a reservoir for the agent and a flow control portion operably connected to the reservoir. The device also includes a valve for releasing the agent from the flow control portion and a pump for flowing air to mix with the agent released by the valve and for flowing the agent and air mixture out of the device. Methods of delivering a vaporized agent to a subject are also provided. The methods include storing a liquid agent in a reservoir of a device and flowing the agent into a flow control chamber to change the agent to a gas. The methods also include mixing the agent in gas form with air and flowing the agent and air mixture out of the device to be delivered to a subject.

Abstract: A method of treating cardiovascular disorders and diseases in a subject in need therof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.